VIDEO: Novel oral therapy drug safe, effective for wet AMD

SAN FRANCISCO —Twice daily dosing of oral AKST4290 over the course of 6 weeks improved visual acuity in patients with neovascular age-related macular degeneration, according to a presenter at the American Academy of Ophthalmology annual meeting.
“Further development of the drug is being planned [in] a randomized phase 2b study,” Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, told Ocular Surgery News. “Subsequently, a phase 3 trial and discussions are underway for trials with diabetic macular edema and edema

Full Story →